Hölter S M, Danysz W, Spanagel R
Max Planck Institute of Psychiatry, Drug Abuse Group, Munich, Germany.
Eur J Pharmacol. 1996 Oct 31;314(3):R1-2. doi: 10.1016/s0014-2999(96)00670-x.
Rats consuming alcohol voluntarily for a long time show increased alcohol consumption after a phase of alcohol deprivation and this might reflect increased craving for alcohol. Administration of memantine (1-amino-3,5-dimethyl-adamantane), a clinically used uncompetitive NDMA receptor antagonist, resulted in a significant reduction of the alcohol deprivation effect without any sedative, dysphoric or stimulant side-effects. The dose of memantine used (4.8 mg/day) resulted in serum levels close to the therapeutic range in humans. These results indicate that memantine may have therapeutical potential as an anti-craving drug for alcohol.
长期自愿饮酒的大鼠在经历一段酒精戒断期后，酒精摄入量会增加，这可能反映出对酒精的渴望增加。美金刚（1-氨基-3,5-二甲基金刚烷）是一种临床上使用的非竞争性N-甲基-D-天冬氨酸（NDMA）受体拮抗剂，给予美金刚可显著降低酒精戒断效应，且无任何镇静、烦躁或兴奋的副作用。所用美金刚剂量（4.8毫克/天）导致血清水平接近人类治疗范围。这些结果表明，美金刚作为一种抗酒精渴望药物可能具有治疗潜力。
